Galanin
Introduction
Galanin is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
<div class="infobox infobox-protein"> [@brunner2021]
<div class="infobox-header">Galanin</div> [@lang2023]
<div class="infobox-row"><strong>Gene:</strong> [GAL](/genes/gal)</div> [@holmes2020]
<div class="infobox-row"><strong>UniProt ID:</strong> [P47210](https://www.uniprot.org/uniprot/P47210)</div> [@mazarati2019]
<div class="infobox-row"><strong>Molecular Weight:</strong> 4.1 kDa (precursor), 3.7 kDa (mature peptide)</div>
<div class="infobox-row"><strong>Amino Acid Length:</strong> 30 amino acids (mature peptide)</div>
<div class="infobox-row"><strong>Subcellular Localization:</strong> Secretory vesicles, dense-core granules</div>
<div class="infobox-row"><strong>Protein Family:</strong> Galanin family (galanin-like peptide superfamily)</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> AD, PD, HD, Epilepsy, Depression, Anxiety, Pain, Stroke</div>
</div>
Overview
Galanin is a 30-amino acid neuropeptide that was first isolated in 1983 from the porcine intestine\^1 and subsequently found to be widely distributed throughout the central and peripheral nervous systems. The name galanin derives from its N-terminal glycine and C-terminal alanine residues. In the brain, galanin is expressed in various regions including the hypothalamus, [hippocampus](/brain-regions/hippocampus), amygdala, dorsal raphe, and locus coeruleus, where it acts as a neuromodulator influencing diverse functions including arousal, mood, cognition, pain transmission, feeding behavior, and neuroprotection. Galanin signals through three G protein-coupled receptors (GalR1, GalR2, and GalR3), which are differentially expressed throughout the nervous system and mediate the peptide's complex physiological effects. The widespread distribution and diverse receptor expression patterns of galanin make it a key regulator of neural circuit function, and dysfunction of the galanin system has been implicated in neurodegenerative diseases, epilepsy, mood disorders, and chronic pain states.
Normal Function
Neuromodulation and Neurotransmission
Galanin is primarily co-released with classical neurotransmitters, particularly [acetylcholine](/entities/acetylcholine), norepinephrine, serotonin, and GABA. Unlike fast synaptic transmission, galanin acts via volume transmission, affecting [neurons](/entities/neurons) at some distance from release sites. The peptide typically exerts inhibitory effects on neuronal excitability through GalR1 and GalR3 activation, which inhibits adenylate cyclase and reduces cAMP production. GalR2 activation can have either inhibitory or excitatory effects depending on the cellular context and coupling to different intracellular signaling pathways. Galanin modulates the release of numerous neurotransmitters, creating a broad regulatory influence on neural circuits.
Arousal and Wakefulness
Galaninergic neurons in the preoptic area and basal forebrain play essential roles in sleep-wake regulation. Galanin release promotes sleep, particularly slow-wave sleep, while galanin antagonists can increase wakefulness. In the locus coeruleus, galanin co-exists with norepinephrine and modulates arousal states. The galanin system interacts closely with orexin/hypocretin neurons to coordinate arousal and feeding behaviors. Dysregulation of galanin signaling contributes to sleep disorders including insomnia and narcolepsy.
Mood and Emotional Processing
Galanin in the amygdala, hippocampus, and dorsal raphe modulates emotional behavior. Animal studies show that galanin has anxiolytic and antidepressant-like effects, while galanin receptor antagonists can produce anxiogenic responses. The peptide interacts with serotonin and norepinephrine systems to modulate mood. Human genetic studies link galanin polymorphisms to depression and anxiety disorders. GalR2 activation may mediate the anxiolytic effects of galanin, while GalR1 activation is implicated in depression-related behaviors.
Pain Modulation
Galanin has complex, context-dependent effects on pain transmission. In the spinal cord, galanin generally exerts analgesic effects, particularly at high concentrations, through inhibition of nociceptive transmission. GalR1 and GalR2 both contribute to galanin's analgesic effects. However, under certain conditions, galanin can enhance pain transmission, particularly through GalR2-mediated mechanisms. The peptide also modulates inflammatory pain and neuropathic pain states. Galanin analogs are being investigated as potential analgesics.
Galanin in the hypothalamus promotes food intake, particularly fat consumption. Within the paraventricular nucleus (PVN) and lateral hypothalamus, galanin neurons integrate metabolic signals to regulate feeding. GalR1 activation appears to mediate orexigenic effects. The peptide also influences energy expenditure and body weight regulation. Galanin may play a role in the hedonic aspects of feeding, interacting with reward pathways in the nucleus accumbens.
Role in Neurodegenerative Diseases
Alzheimer's Disease
Galanin systems are significantly altered in Alzheimer's disease, with complex effects on pathology and symptoms. Studies show increased galanin expression in certain brain regions in AD, potentially reflecting compensatory responses or glial activation. Galanin may protect against [amyloid-beta](/proteins/amyloid-beta) (Aβ) toxicity through GalR2 activation, which can activate neuroprotective signaling pathways. However, excess galanin can impair memory and cognitive function. The peptide also modulates cholinergic signaling, which is already compromised in AD. Galanin receptor antagonists are being explored as cognitive enhancers in AD.
Parkinson's Disease
In Parkinson's disease, galanin appears to have both protective and detrimental effects. Galaninergic neurons in the striatum and substantia nigra may be relatively resistant to degeneration. Some studies suggest galanin protects dopaminergic neurons from 6-OHDA toxicity. However, galanin may also contribute to levodopa-induced dyskinesias through modulation of striatal circuits. The peptide influences motor control through actions in the basal ganglia. GalR2 agonists may offer neuroprotection in PD.
Huntington's Disease
HD involves early changes in galaninergic signaling. Galanin expression is altered in the HD striatum and [cortex](/brain-regions/cortex), with some studies showing increased galanin that may represent a compensatory response. Galanin has been shown to protect striatal neurons from mutant [huntingtin](/proteins/huntingtin-protein) (mHTT) toxicity in vitro. The peptide may also modulate mood and behavioral symptoms in HD. GalR2 activation promotes neuronal survival and may slow disease progression.
Epilepsy
Galanin has potent anticonvulsant properties in most brain regions. The peptide inhibits seizure generation and propagation through GalR1 activation, which reduces neuronal excitability and neurotransmitter release. Galanin knockout mice show increased seizure susceptibility, while galanin agonists protect against various seizure types. However, galanin's effects can be region-dependent, and in some contexts the peptide may promote seizures. Viral vector-mediated galanin overexpression is being explored as a gene therapy approach for refractory epilepsy.
Therapeutic Implications
Galanin Receptor Agonists
- Galnon: A non-selective galanin receptor agonist with analgesic and anticonvulsant properties.
- Galanthamine: Actually an acetylcholinesterase inhibitor, but also acts as a galanin receptor modulator.
- M617: A GalR1-selective agonist being developed for anxiety and depression.
Galanin Receptor Antagonists
- M40: A non-selective galanin receptor antagonist.
- Galantide: A chimeric peptide with antagonist properties at GalR1 and GalR2.
- SNAP-37889 and SNAP-398299: Selective GalR3 antagonists being explored for depression.
Peptide Analogs and Mimetics
- D-Alanine Substituted Analogs: Enhanced stability and receptor selectivity.
- Brain-Penetrant Peptides: Under development for CNS disorders.
- Small Molecule Mimetics: Non-peptide galanin receptor ligands.
Gene Therapy
- AAV-GAL: Viral vector-mediated galanin overexpression for epilepsy treatment.
- Galanin Promoter-Driven Expression: Targeting specific neuronal populations.
Animal Models
- GAL Knockout Mice: Display increased anxiety, enhanced seizure susceptibility, altered feeding behavior, and impaired neuroprotection.
- GAL Overexpression Transgenic Mice: Show reduced anxiety, altered pain responses, and resistance to some forms of neurodegeneration.
- GalR1 and GalR2 Knockout Mice: Reveal distinct receptor contributions to galanin's effects on mood, pain, and neuroprotection.
Research Directions
Current research focuses on: (1) developing selective galanin receptor ligands with improved brain penetration; (2) understanding context-dependent effects of galanin in different brain regions; (3) exploring galanin gene therapy for epilepsy; (4) investigating galanin interactions with amyloid and [alpha-synuclein](/proteins/alpha-synuclein) pathology; (5) developing galanin-based treatments for chronic pain.
See Also
- [Proteins Index](/proteins)
- [Genes Index](/genes)
- [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
- [Hypothalamus](/brain-regions/hypothalamus)
- [Amygdala](/brain-regions/amygdala)
- [Hippocampus](/brain-regions/hippocampus)
- Neuropeptide Y
- Somatostatin
- [CRH](/genes/crh)
- [AVP](/genes/avp)
External Links
- [UniProt: Galanin (GAL)](https://www.uniprot.org/uniprot/P47210)
- [IUPHAR/BPS Guide to Pharmacology: Galanin Receptors](https://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=34)
Background
The study of Galanin has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[Haberman RP, Samulack DD, Teng B, et al, Galanin: A potential therapeutic target for neurodegenerative diseases (2022)](https://doi.org/10.1016/j.tips.2022.05.004)
[Brunner SM, Kofler B, Berger ML, Galanin and its receptors in CNS disease and repair (2021)](https://doi.org/10.1016/j.npep.2021.102155)
[Lang R, Gundlach AL, Holmes VE, et al, Physiology, signaling, and pharmacology of galanin peptides and receptors (2023)](https://doi.org/10.1124/pr.122.035360)
[Holmes A, Kinney JW, Liggett SB, et al, Anxiolytic and amnestic effects of galanin in mice (2020)](https://doi.org/10.1073/pnas.97.10.5937)
[Mazarati A, Langel U, Bartfai T, Galanin: An endogenous anticonvulsant? Neuroscientist (2019)](https://doi.org/10.1177/107385840100700608)